Long‐term Therapeutic Efficacy of Lamivudine Compared With Interferon‐α in Children with Chronic Hepatitis B: The Younger the Better

Abstract

Long-term treatment of lamivudine led to significant improvement in the seroconversion rate of HBeAg in children with chronic hepatitis B compared with IFN-alpha therapy. Furthermore, in preschool-age children, it led to significant improvement in the seroconversion rate of HBeAg and HBsAg compared with school-age children.